Middle East Conflict Threatens Global Economic Stability, World Bank Warns 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
U.S. Inflation Surges in March as Iran War and Tariffs Drive Prices Higher 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
Asian Currencies Hold Steady as Middle East Ceasefire Doubts Weigh on Markets 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Gulf Ceasefire Cracks Rattle Asian Markets and Push Oil Prices Higher 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
U.S. Futures Slip as Iran Ceasefire Uncertainty and CPI Data Weigh on Markets 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Trump Slams Iran Over Strait of Hormuz Oil Restrictions Amid Fragile Ceasefire 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
White House Warns Staff Over Insider Trading Amid Suspicious Oil Market Bets 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
Merck & Co Inc. gets the green light from the Japanese health ministry for its COVID-19 anti-viral pill. The health officials recommended the approval of the said medicine late last week.
The approval of the Merck coronavirus pill is said to be part of the country’s Prime Minister Fumio Kishida’s plan to introduce and distribute new treatments by the end of the year as the growing cases of Omicron variant infection is becoming a very serious concern.
According to Inquirer.net, the committee’s decision has led to the shipments of around 200,000 doses starting this weekend. This is just the preparation and start of the deliveries as per the announcement of the country’s prime minister.
“I am convinced the distribution of this drug is a major step forward for our nation’s COVID–19 handling,” Shigeyuki Goto, Japan’s health minister, told the press after the announcement of the panel’s approval of Merck’s COVID-19 treatment pill.
He added that some of the country’s pharmacies and medical institutions are expected to begin receiving the medicine as early as next Monday. Moreover, it was said that Japan is really laying bets on oral treatments to prevent cases of severe infections and deaths should a sixth wave of the pandemic arise.
Based on the report, Japan agreed to pay $1.2 billion to Merck and its partner Ridgeback Biotherapeutics for the shipment of 1.6 million courses of molnupiravir. PM Kishida also said last week, the government signed a deal for two million doses of another anti-viral treatment pill and this was developed by Pfizer.
In the U.S., health regulators also authorized the use of the Merck pill for some high-risk adult patients. Many countries are now rushing to purchase the said Merck’s molnupiravir due to promising results during trials.
“As a single oral medicine that can be taken at home, early treatment with molnupiravir significantly reduced the risk of hospitalization or death in patients at high risk for progressing to severe COVID-19,” Merck research laboratories president, Dr. Dean Y. Li, said in a press release. “Importantly for patients, there were markedly fewer deaths among those taking molnupiravir in our clinical study and we believe that it will be a critical addition to the measures available to help curb the impact of COVID-19 on patients, healthcare systems, and public health in Japan.”
